Notably, sub-chronic treatment with GR selective antagonist, RU-43044, has also been shown to reverse corticosterone-induced depression-like behavior (176) suggesting GR as a potential molecular target to combat HPA axis dysregulation. Here, NR3C1 is linked to major depressive disorder.